Logo image of XOMA

XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

NASDAQ:XOMA - Nasdaq - US98419J2069 - Common Stock - Currency: USD

23.85  -0.75 (-3.05%)

After market: 23.85 0 (0%)

Fundamental Rating

4

XOMA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. There are concerns on the financial health of XOMA while its profitability can be described as average. XOMA is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

XOMA had negative earnings in the past year.
XOMA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XOMA reported negative operating cash flow in multiple years.
XOMA Yearly Net Income VS EBIT VS OCF VS FCFXOMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

With an excellent Return On Assets value of -8.74%, XOMA belongs to the best of the industry, outperforming 85.15% of the companies in the same industry.
With an excellent Return On Equity value of -21.96%, XOMA belongs to the best of the industry, outperforming 84.08% of the companies in the same industry.
XOMA has a Return On Invested Capital of 0.19%. This is amongst the best in the industry. XOMA outperforms 91.59% of its industry peers.
Industry RankSector Rank
ROA -8.74%
ROE -21.96%
ROIC 0.19%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMA Yearly ROA, ROE, ROICXOMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

XOMA's Operating Margin of 1.03% is amongst the best of the industry. XOMA outperforms 91.95% of its industry peers.
XOMA does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 1.03%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMA Yearly Profit, Operating, Gross MarginsXOMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMA is destroying value.
Compared to 1 year ago, XOMA has more shares outstanding
XOMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XOMA is higher compared to a year ago.
XOMA Yearly Shares OutstandingXOMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMA Yearly Total Debt VS Total AssetsXOMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

XOMA has an Altman-Z score of -6.05. This is a bad value and indicates that XOMA is not financially healthy and even has some risk of bankruptcy.
XOMA has a worse Altman-Z score (-6.05) than 63.86% of its industry peers.
XOMA has a Debt/Equity ratio of 1.18. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of XOMA (1.18) is worse than 78.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF N/A
Altman-Z -6.05
ROIC/WACC0.01
WACC13.18%
XOMA Yearly LT Debt VS Equity VS FCFXOMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.54 indicates that XOMA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.54, XOMA is in line with its industry, outperforming 57.42% of the companies in the same industry.
A Quick Ratio of 5.54 indicates that XOMA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.54, XOMA is in line with its industry, outperforming 58.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 5.54
XOMA Yearly Current Assets VS Current LiabilitesXOMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.50% over the past year.
XOMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 663.79%.
Measured over the past years, XOMA shows a quite strong growth in Revenue. The Revenue has been growing by 9.17% on average per year.
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%

3.2 Future

XOMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.94% yearly.
XOMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.09% yearly.
EPS Next Y73.1%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
EPS Next 5YN/A
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XOMA Yearly Revenue VS EstimatesXOMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMA Yearly EPS VS EstimatesXOMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

XOMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
XOMA is valuated quite expensively with a Price/Forward Earnings ratio of 556.72.
Based on the Price/Forward Earnings ratio, XOMA is valued cheaper than 87.30% of the companies in the same industry.
XOMA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.13.
Industry RankSector Rank
PE N/A
Fwd PE 556.72
XOMA Price Earnings VS Forward Price EarningsXOMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300 400 500

4.2 Price Multiples

90.88% of the companies in the same industry are more expensive than XOMA, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 249.66
XOMA Per share dataXOMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as XOMA's earnings are expected to grow with 39.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.15%
EPS Next 3Y39.94%

More info and screens

0

5. Dividend

5.1 Amount

XOMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (6/13/2025, 4:30:02 PM)

After market: 23.85 0 (0%)

23.85

-0.75 (-3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners62.7%
Inst Owner Change0.49%
Ins Owners1.39%
Ins Owner Change-34.66%
Market Cap285.48M
Analysts82
Price Target65.96 (176.56%)
Short Float %1.5%
Short Ratio5.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-29.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.13%
Min EPS beat(2)-45.44%
Max EPS beat(2)119.7%
EPS beat(4)2
Avg EPS beat(4)56.23%
Min EPS beat(4)-256.98%
Max EPS beat(4)407.67%
EPS beat(8)3
Avg EPS beat(8)22.51%
EPS beat(12)3
Avg EPS beat(12)-16.39%
EPS beat(16)5
Avg EPS beat(16)-21.54%
Revenue beat(2)1
Avg Revenue beat(2)59.22%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.22%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)22.27%
Revenue beat(12)6
Avg Revenue beat(12)0.36%
Revenue beat(16)7
Avg Revenue beat(16)-7.52%
PT rev (1m)0%
PT rev (3m)-18.66%
EPS NQ rev (1m)-37.92%
EPS NQ rev (3m)-6.56%
EPS NY rev (1m)0%
EPS NY rev (3m)1.59%
Revenue NQ rev (1m)22.56%
Revenue NQ rev (3m)15.48%
Revenue NY rev (1m)36.77%
Revenue NY rev (3m)31.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 556.72
P/S 6.43
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 4.82
EV/EBITDA 249.66
EPS(TTM)-1.14
EYN/A
EPS(NY)0.04
Fwd EY0.18%
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS3.71
BVpS7.07
TBVpS4.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.74%
ROE -21.96%
ROCE 0.24%
ROIC 0.19%
ROICexc 0.36%
ROICexgc 0.49%
OM 1.03%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF N/A
Debt/EBITDA 82.05
Cap/Depr 2651.64%
Cap/Sales 45.45%
Interest Coverage 0.04
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 5.54
Altman-Z -6.05
F-Score5
WACC13.18%
ROIC/WACC0.01
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
EPS Next Y73.1%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
EPS Next 5YN/A
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A
EBIT growth 1Y102%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.83%
EBIT Next 3Y51.02%
EBIT Next 5YN/A
FCF growth 1Y16.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.67%
OCF growth 3YN/A
OCF growth 5YN/A